Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The company’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating...
1880 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
CEO & Director
Total Annual Compensation: $376.3K
Co-Founder, President, Corporate Secretary & Director
Total Annual Compensation: $441.2K
Co-Founder, Executive Chairman & Chief Strategic Officer
Total Annual Compensation: $405.9K
Compensation as of Fiscal Year 2016.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals Receives Non-Compliance Notice From Nasdaq
Jun 9 17
On June 7, 2017, Ritter Pharmaceuticals, Inc. received a letter (Notice) from The Nasdaq Stock Market (Nasdaq) notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the common stock on The Nasdaq Capital Market. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until December 4, 2017 to regain compliance with the Minimum Bid Price Requirement. During the compliance period, the Company’s shares of common stock will continue to be listed and traded on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. In the event the Company is not in compliance with the Minimum Bid Price Requirement by December 4, 2017 the Company may be afforded a second 180 calendar day grace period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. In addition, the Company would be required to provide written notice of its intention to cure the minimum bid price deficiency during this second 180 day compliance period by effecting a reverse stock split, if necessary. The Company intends to actively monitor the bid price for its common stock between now and December 4, 2017 and will consider available options to regain compliance with the Minimum Bid Price Requirement.
Ritter Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2017
May 9 17
Ritter Pharmaceuticals, Inc. announced unaudited earnings results for the first quarter ended March 31, 2017. For the period, the company's operating loss was $1,681,181 compared to $3,150,230 a year ago. The company reported a net loss attributable to common stockholders of approximately $1.7 million compared to a net loss of approximately $3.1 million for the first quarter of 2016. Basic and diluted net loss per share was $0.14 for the three months ended March 31, 2017 compared to basic and diluted net loss per share of $0.36 for the same period in 2016.
Ritter Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2017
Apr 21 17
Ritter Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2017, at 09:00 Pacific Standard Time. Location: 1901 Avenue of the Stars, Suite 700 Los Angeles, CA 90067-6078 United States Agenda: To elect as directors the eight nominees; to ratify the appointment of Mayer Hoffman McCann P.C., as independent registered public accounting firm for the fiscal year ending December 31, 2017; to approve the amendment of the company's 2015 Equity Incentive Plan, in substantially the form of Annex A to this proxy statement, to increase the number of shares that may be issued pursuant to awards thereunder by 838,000 shares to an aggregate of (i) 1,641,289 shares plus (ii) any shares that were available for grant under the 2008 Stock Plan and the 2009 Stock Plan on the effective date of the 2015 Equity Incentive Plan or were subject to awards under the Prior Plans that, after the effective date of the 2015 Equity Incentive Plan, were or are forfeited or lapse unexercised or were or are settled in cash and are not issued under the Prior Plans.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|